Dishman Carbogen Amcis Limited (DCAL.NS)
- Previous Close
192.25 - Open
193.70 - Bid 189.85 x --
- Ask 190.00 x --
- Day's Range
189.20 - 193.95 - 52 Week Range
116.20 - 283.00 - Volume
202,405 - Avg. Volume
917,445 - Market Cap (intraday)
29.789B - Beta (5Y Monthly) 1.20
- PE Ratio (TTM)
-- - EPS (TTM)
-9.73 - Earnings Date May 30, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date Sep 12, 2019
- 1y Target Est
--
Dishman Carbogen Amcis Limited provides contract research and manufacturing services to the pharmaceutical industry in India and internationally. The company operates through Contract Research and Manufacturing Services and Marketable Molecules segments. It also manufactures and supplies bulk drugs, active pharmaceutical ingredients, phase transfer catalysts, quaternary ammonium compounds, phosphoranes, wittig reagents, vitamin D products, fine chemicals, hand and body wash, sanitizers, antiseptics, vitamin D analogues, cholesterol, lanolin-related products, disinfectant formulations, and various pharmaceutical and cosmetic-related products, as well as generic and highly potent active pharmaceutical ingredients. The company was founded in 1983 and is headquartered in Ahmedabad, India. Dishman Carbogen Amcis Limited operates as a subsidiary of Adimans Technologies LLP.
imdcal.comRecent News: DCAL.NS
Performance Overview: DCAL.NS
Trailing total returns as of 5/29/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: DCAL.NS
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: DCAL.NS
Valuation Measures
Market Cap
30.12B
Enterprise Value
48.35B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
1.18
Price/Book (mrq)
0.53
Enterprise Value/Revenue
1.89
Enterprise Value/EBITDA
20.05
Financial Highlights
Profitability and Income Statement
Profit Margin
-5.98%
Return on Assets (ttm)
--
Return on Equity (ttm)
--
Revenue (ttm)
25.8B
Net Income Avi to Common (ttm)
-1.54B
Diluted EPS (ttm)
-9.73
Balance Sheet and Cash Flow
Total Cash (mrq)
4.73B
Total Debt/Equity (mrq)
39.99%
Levered Free Cash Flow (ttm)
--